Table 2 Baseline characteristics
Azithromycin group (n = 47) | Placebo group (n = 45) | |
|---|---|---|
Male | 22 (46·8%) | 18 (40%) |
Age (years) | 64·7 (10·2) | 64·9 (10·2) |
Current smoker | 20 (43%) | 9 (20%) |
AECOPD in past year | 4·0 (1·2) | 4·0 (1·1) |
Hospitalisation due to AECOPD | 1·0 (1·1) | 0·7 (0·8) |
Spirometry after bronchodilation | ||
FEV1(L) | 1·1 (0·47) | 1·1 (0·43) |
FEV1(% of predicted) | 44·2 (19·3) | 45·0 (19·5) |
FVC (L) | 2·9 (0·8) | 2·7 (0·92) |
FVC (% of predicted) | 92·5 (22·2) | 88·9 (20·3) |
FEV1/FVC (%) | 38·0 (11·7) | 40·3 (12·4) |
GOLD stages | ||
I | 2 (4·3%) | 3 (6·7%) |
II | 14 (29·8%) | 12 (26·7%) |
III | 18 (38·3%) | 20 (44·4%) |
IV | 13 (27·7%) | 10 (22·2%) |